Tango Therapeutics GAAP EPS of -$0.39
- Tango Therapeutics press release (TNGX): Q3 GAAP EPS of -$0.39.
Net loss for the three months ended September 30, 2026 was $68.4 million, or $0.39 per share (basic and diluted), compared to a net income of $15.9 million, or $0.14 per share (basic) and $0.13 per share (diluted), in the same period in 2025. Net
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.